keyword
MENU ▼
Read by QxMD icon Read
search

exenatid

keyword
https://www.readbyqxmd.com/read/29780260/efficacy-and-safety-profile-of-once-weekly-dulaglutide-in-type-2-diabetes-a-report-on-the-emerging-new-data
#1
REVIEW
Anne J Kugler, Michael L Thiman
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to -1.64% over 52-104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of -1.4% to -1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively...
2018: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29773932/effectiveness-and-tolerability-of-therapy-with-once-weekly-exenatide-versus-basal-insulin-among-injectable-naive-patients-with-type-2-diabetes-in-a-real-world-setting-in-the-united-states
#2
Anita M Loughlin, Qing Qiao, Anthony P Nunes, Stephen M Ezzy, Laura Yochum, C Robin Clifford, Robert V Gately, David D Dore, John D Seeger
A propensity-matched cohort study compared injectable-naive patients with type 2 diabetes initiating exenatide once weekly (EQW) or basal insulin (BI), from 2012 through 2015, within a U.S. electronic health record database. A1C and weight were obtained as observed or multiply imputed values at baseline and quarterly for 1 year (Q1-Q4). Hypoglycemia and gastrointestinal symptoms were identified using diagnostic codes and clinical notes. EQW ( n = 2,008) and BI ( n = 4,016) cohorts were comparable at baseline (mean A1C and weight: EQW, 8...
May 2018: Diabetes Spectrum: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29766634/semaglutide-induces-weight-loss-in-subjects-with-type-2-diabetes-regardless-of-baseline-bmi-or-gastrointestinal-adverse-events-in-sustain-1-5-trials
#3
Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John Ph Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence A Leiter
AIMS: Semaglutide, a new once-weekly glucagon-like peptide 1 analogue for the treatment of type 2 diabetes, demonstrated superior reductions in HbA1c and superior weight loss (by 2.3-6.3 kg) versus different comparators across the SUSTAIN 1-5 trials; the contributing factors to weight loss are not established. This post hoc analysis assessed the effect of baseline body mass index (BMI), and of occurrence of nausea and/or vomiting, on semaglutide-induced weight loss. MATERIALS AND METHODS: Subjects with inadequately controlled type 2 diabetes (drug-naïve or on background treatment) were randomized to subcutaneous semaglutide 0...
May 15, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29765326/descriptions-of-adverse-drug-reactions-are-less-informative-in-forums-than-in-the-french-pharmacovigilance-database-but-provide-more-unexpected-reactions
#4
Pierre Karapetiantz, Florelle Bellet, Bissan Audeh, Jérémy Lardon, Damien Leprovost, Rim Aboukhamis, François Morlane-Hondère, Cyril Grouin, Anita Burgun, Sandrine Katsahian, Marie-Christine Jaulent, Marie-Noëlle Beyens, Agnès Lillo-Le Louët, Cédric Bousquet
Background: Social media have drawn attention for their potential use in Pharmacovigilance. Recent work showed that it is possible to extract information concerning adverse drug reactions (ADRs) from posts in social media. The main objective of the Vigi4MED project was to evaluate the relevance and quality of the information shared by patients on web forums about drug safety and its potential utility for pharmacovigilance. Methods: After selecting websites of interest, we manually evaluated the relevance of the content of posts for pharmacovigilance related to six drugs (agomelatine, baclofen, duloxetine, exenatide, strontium ranelate, and tetrazepam)...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29765207/adherence-to-antihyperglycemic-medications-and-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-clinical-consequences-and-strategies-for-improvement
#5
REVIEW
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella, Antonella Corcos
Adherence to antihyperglycemic medications is often suboptimal in patients with type 2 diabetes, and this can contribute to poor glycemic control, increased hospitalization, and the development of diabetic complications. Reported adherence rates to antihyperglycemics vary widely among studies, and this may be related to differences in methodology for measuring adherence, patient populations, and other factors. Poor adherence may occur regardless of the specific regimen used and whether therapy is oral or injectable, and can be especially common in chronic, asymptomatic conditions, such as type 2 diabetes...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29762878/risk-of-hypoglycemia-after-concomitant-use-of-antidiabetic-antihypertensive-and-antihyperlipidemic-medications-a-database-study
#6
Masahiko Gosho
Hypoglycemia is the most important complication of antidiabetic medications. Most patients with diabetes mellitus take multiple medications. In this study, we explored clinical drug-drug interactions that result in hypoglycemia by analyzing the Japanese Adverse Drug Event Report (JADER) database. The primary outcome was the report of hypoglycemia. The Norén and Gosho methods, which quantitatively measure the discrepancy between the observed and expected number of adverse events under the combination of 2 drugs, were used as the criteria for detecting drug-drug interactions...
May 15, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29756388/semaglutide-for-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#7
Panagiotis Andreadis, Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Manolopoulos, Eleni Bekiari, David R Matthews, Apostolos Tsapas
AIM: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. METHODS: We searched major electronic databases and grey literature sources for randomised controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c . Secondary endpoints included change from baseline in body weight, blood pressure, heart rate, and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy...
May 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29754323/the-effects-of-exenatide-and-metformin-on-endothelial-function-in-newly-diagnosed-type-2-diabetes-mellitus-patients-a-case-control-study
#8
Yanjin Hu, Jia Liu, Guang Wang, Yuan Xu
INTRODUCTION: Exenatide is a new antidiabetic glucagon-like peptide-1 receptor agonist. In addition to its hypoglycemic effect, exenatide may have a potential protective benefit on vascular endothelial function. This study attempted to compare the effects of exenatide and traditional antidiabetic drug metformin treatment on endothelial function in overweight patients with type 2 diabetes. METHODS: Ninety overweight patients with newly diagnosed type 2 diabetes were recruited; 45 patients received exenatide (Exe) treatment and 45 patients received metformin (Met) treatment for 12 weeks...
May 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744819/comparison-of-glycemic-variability-in-chinese-t2dm-patients-treated-with-exenatide-or-insulin-glargine-a-randomized-controlled-trial
#9
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu
INTRODUCTION: Increasing the frequency of blood glucose monitoring aids the evaluation of glycemic variability and blood glucose control by antidiabetic drugs. It remains unclear, however, whether GLP-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes mellitus (T2DM) patients who are inadequately controlled by metformin. We used a continuous glucose monitoring system (CGMS) to compare patients on a GLP-1 receptor agonist with patients on basal insulin in terms of glycemic variability...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29740874/short-term-combined-treatment-with-exenatide-and-metformin-is-superior-to-glimepiride-combined-metformin-in-improvement-of-serum-testosterone-levels-in-type-2-diabetic-patients-with-obesity
#10
N Shao, X-Y Yu, Y-M Yu, B-W Li, J Pan, W-H Wu, H-J Zhang, X-F Ma, M Hao, H-Y Kuang
Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T). We aimed to determine whether exenatide (EXE) combined metformin (MET) treatment has a better effect on serum total testosterone (TT) levels than glimepiride (GLI) combined MET treatment in men with T2D and obesity. In a multicentre, 12-week observational study, 176 obese T2D men with failed glycaemic control were included in the study: ninety men (mean age, 43.00 ± 8.50 years) in EXE + MET group and 86 men (mean age, 44...
May 8, 2018: Andrologia
https://www.readbyqxmd.com/read/29696350/exenatide-preserves-trabecular-bone-microarchitecture-in-experimental-ovariectomized-rat-model
#11
Elmin Eminov, Ismet Hortu, Levent Akman, Oytun Erbas, Altug Yavasoglu, Teksin Cirpan
PURPOSE: The aim of this study is to investigate effects of exenatide (Glucagon-Like Peptide Agonist) replacement on bone mineral density (BMD) and microarchitecture in a surgical menopause-induced osteoporosis model in rats. METHODS: In this study, 24 female Sprague-Dawley albino mature rats were used. Rats were assigned either to the group ovariectomized administered exenatide or to the control group. Bone Mineral Density (BMD), plasma cytokine levels and histomorphometric analysis were measured...
April 25, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29693361/generalizability-of-glucagon-like-peptide-1-receptor-agonist-cardiovascular-outcome-trials-enrollment-criteria-to-the-us-type-2-diabetes-population
#12
Eric T Wittbrodt, James M Eudicone, Kelly F Bell, Devin M Enhoffer, Keith Latham, Jennifer B Green
OBJECTIVES: Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general population. This study examined the proportion of adults eligible for 7 ongoing or completed glucagon-like peptide-1 receptor agonist (GLP-1 RA) CVOTs. STUDY DESIGN: This cross-sectional, retrospective, cohort study compared data from the National Health and Nutrition Examination Survey (NHANES) with published eligibility criteria from GLP-1 RA CVOTs...
April 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29687620/semaglutide-as-a-therapeutic-option-for-elderly-patients-with-type-2-diabetes-pooled-analysis-of-the-sustain-1-5-trials
#13
Mark Warren, Louis Chaykin, David Trachtenbarg, Gurudutt Nayak, Nelun Wijayasinghe, Bertrand Cariou
This pooled analysis evaluated the efficacy and safety of semaglutide vs comparators in non-elderly (<65 years) and elderly (≥65 years) patients with type 2 diabetes (T2D) across the SUSTAIN 1-5 trials. Patients were randomised to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin. Primary objective was change in HbA1c ; secondary objectives were change in body weight and safety. Mean HbA1c decreased from baseline by 1.2-1.5% and 1.5-1.9% vs 0.0-0.9% (non-elderly, n=3,045) and by 1...
April 23, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29677253/in-type-2-diabetes-weekly-semaglutide-reduced-hba1c-and-increased-weight-loss-more-than-weekly-exenatide-er
#14
Eleni Bekiari, Thomas Karagiannis, Apostolos Tsapas
No abstract text is available yet for this article.
April 17, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29663628/exenatide-effects-on-gastric-emptying-and-oral-glucose-appearance-in-plasma-a-quantitative-assessment-using-an-integrative-systems-pharmacology-model
#15
Veronika Voronova, Kirill Zhudenkov, Robert C Penland, David W Boulton, Gabriel Helmlinger, Kirill Peskov
Glucagon-like peptide (GLP)-1 and synthetic GLP-1 receptor agonists (GLP-1RA) slow gastric emptying rate (GER), thereby decreasing the Glucose Rate of Appearance (GluRA) in plasma, which may contribute to postprandial plasma glucose (PPG) stabilization under GLP-1RA treatment. A quantitative systems pharmacology (QSP) approach was used to evaluate the effect of exenatide immediate release (IR), a short-acting GLP-1RA, on GER and GluRA. The proposed model is based on the data from multiple published sources including: (1) GLP-1 and exenatide plasma concentration-time profiles; (2) GER estimates under placebo, GLP-1 or exenatide IR dosing; (3) GluRA measurements upon food intake...
April 16, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29650603/top-studies-relevant-to-primary-care-practice
#16
REVIEW
Danielle Perry, Michael R Kolber, Christina Korownyk, Adrienne J Lindblad, Jamil Ramji, Joey Ton, G Michael Allan
OBJECTIVE: To summarize 10 high-quality studies from 2017 that have strong relevance to primary care practice. QUALITY OF EVIDENCE: Study selection involved routine literature surveillance by a group of primary care health professionals. This included screening abstracts of important journals and Evidence Alerts, as well as searching the American College of Physicians Journal Club. MAIN MESSAGE: Topics of the 2017 articles include whether treating subclinical hypothyroidism improves outcomes or symptoms; whether evolocumab reduces cardiovascular disease as well as low-density lipoprotein levels; whether lifestyle interventions reduce medication use in patients with diabetes; whether vitamin D prevents cardiovascular disease, cancer, or upper respiratory tract infections; whether canagliflozin reduces clinical events in patients with diabetes; how corticosteroid injections affect knee osteoarthritis; whether drained abscesses benefit from antibiotic treatment; whether patients with diabetes benefit from bariatric surgery; whether exenatide reduces clinical events in patients with diabetes; and whether tympanostomy tubes affect outcomes in recurrent acute otitis media or chronic otitis media...
April 2018: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/29619854/tf-ligand-receptor-mediated-exenatide-zn-2-complex-oral-delivery-system-for-penetration-enhancement-of-exenatide
#17
Liping Zhang, Yanan Shi, Yina Song, Dongyu Duan, Xuemei Zhang, Kaoxiang Sun, Youxin Li
Safe and effective oral delivery of peptide is a challenge. Here, we used exenatide and zinc ions (Zn2+ ) to form a complex to explore a meaningful oral-targeted drug-delivery system. Polyethylene glycol-poly(lactic acid-co-glycolic acid) (PEG-PLGA) was used to prepare nanoparticles (NPs) to escape the degradation caused by gastrointestinal enzymes. Transferrin (Tf) was used as a targeting group. PEG-PLGA-NPs and Tf-modified exenatide-Zn2+ -loaded NPs (Tf-PEG-PLGA-NPs) were uniformly sized spheres according to transmission electron microscopy...
April 5, 2018: Journal of Drug Targeting
https://www.readbyqxmd.com/read/29596853/exenatide-has-a-pronounced-effect-on-energy-intake-but-not-energy-expenditure-in-non-diabetic-subjects-with-obesity-a-randomized-double-blind-placebo-controlled-trial
#18
Alessio Basolo, Joshua Burkholder, Kristy Osgood, Alexis Graham, Sarah Bundrick, Joseph Frankl, Paolo Piaggi, Marie S Thearle, Jonathan Krakoff
AIMS: Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. MATERIALS AND METHODS: In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34...
March 26, 2018: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29596830/liposome-encapsulated-clodronate-specifically-depletes-spinal-microglia-and-reduces-initial-neuropathic-pain
#19
Yi-Rui Wang, Xiao-Fang Mao, Hai-Yun Wu, Yong-Xiang Wang
Liposome-encapsulated clodronate (LEC) is a specific depletor of macrophages. Our study characterized the LEC depletory effects, given intrathecally, on spinal microglia and assessed its effects on initiation and maintenance of neuropathic pain. Measured by using the MTT assay, LEC treatment specifically inhibited cell viability of cultured primary microglia, but not astrocytes or neurons, from neonatal rats, with an IC50 of 43 μg/mL. In spinal nerve ligation-induced neuropathic rats, pretreatment (1 day but not 5 days earlier) with intrathecal LEC specifically depleted microglia (but not astrocytes or neurons) in both contralateral and ipsilateral dorsal horns by the same degree (63% vs...
March 28, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29574041/in-vivo-evaluation-of-an-oral-self-emulsifying-drug-delivery-system-sedds-for-exenatide
#20
Claudia Menzel, Thomas Holzeisen, Flavia Laffleur, Sergey Zaichik, Muthanna Abdulkarim, Mark Gumbleton, Andreas Bernkop-Schnürch
BACKGROUND: The aim of the study was to develop an oral self-emulsifying drug delivery system (SEDDS) for exenatide and to evaluate its in vivo efficacy. METHODS: Exenatide was lipidised via hydrophobic ion pairing with sodium docusate (DOC) and incorporated in SEDDS consisting of 35% Cremophor EL, 25% Labrafil 1944, 30% Capmul-PG 8 and 10% propylene glycol. Exenatide/DOC was characterized in terms of lipophilicity evaluating the octanol/water phase distribution (logP)...
March 21, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
keyword
keyword
109678
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"